CRYSVITA Drug Profile

Summary for Tradename: CRYSVITA

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for CRYSVITA

Recent Clinical Trials for CRYSVITA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Kyowa Kirin Co., Ltd.	Phase 4
Kyowa Kirin Pharmaceutical Development Ltd	Phase 1/Phase 2
Yale University	Phase 4

See all CRYSVITA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for CRYSVITA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for CRYSVITA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for CRYSVITA Derived from Patent Text Search

No patents found based on company disclosures

CRYSVITA: Market Dynamics and Financial Trajectory of a Novel FGF23 Regulator

Last updated: February 19, 2026

CRYSVITA, a recombinant human fibroblast growth factor 23 (FGF23) protein, has established a significant market position as the first approved therapy for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). Its development and commercialization by Ultragenyx Pharmaceutical and Takeda Pharmaceutical Company has demonstrated a consistent upward financial trajectory driven by unmet medical needs and expanding indications.

What is CRYSVITA and Its Mechanism of Action?

CRYSVITA (burosumab-twlc) is a monoclonal antibody that binds to and inhibits FGF23. FGF23 is a hormone that plays a critical role in phosphate and vitamin D metabolism. In XLH, mutations in the PHEX gene lead to increased FGF23 production, causing renal phosphate wasting and impaired vitamin D activation, resulting in rickets and osteomalacia. By neutralizing excess FGF23, CRYSVITA restores normal phosphate and vitamin D levels, addressing the underlying pathophysiology of XLH [1]. For TIO, CRYSVITA targets the excess FGF23 produced by certain rare tumors, thereby correcting the associated hypophosphatemia and osteomalacia [2].

What is the Regulatory History and Approval Status of CRYSVITA?

The U.S. Food and Drug Administration (FDA) first approved CRYSVITA in April 2018 for the treatment of XLH in adult and pediatric patients six months of age and older [1]. This marked a significant milestone as the first FDA-approved drug specifically for XLH. In January 2020, the FDA expanded the approval to include pediatric patients one year of age and older [3]. In April 2022, the FDA approved CRYSVITA for the treatment of TIO in adult and pediatric patients six years of age and older [2].

In Europe, the European Medicines Agency (EMA) granted marketing authorization for CRYSVITA in February 2018 for the treatment of rickets and osteomalacia associated with XLH in patients aged one year and older [4]. The EMA subsequently approved it for TIO in December 2020 [5]. CRYSVITA has also received approval in other major markets, including Japan and Canada, for its indicated uses.

What are the Primary Market Indications for CRYSVITA?

CRYSVITA's primary market indications are:

• X-linked Hypophosphatemia (XLH): This is a rare genetic disorder characterized by low phosphate levels in the blood, leading to bone deformities, bone pain, and impaired growth. CRYSVITA addresses the primary driver of XLH by inhibiting excess FGF23 [1].
• Tumor-Induced Osteomalacia (TIO): This is a rare paraneoplastic syndrome caused by the excessive production of FGF23 by benign or malignant tumors. CRYSVITA is used to treat the hypophosphatemia and osteomalacia associated with TIO, particularly when surgical removal of the tumor is not feasible or curative [2].

What is the Market Size and Growth Potential for CRYSVITA?

The market for rare disease therapies, particularly those addressing unmet needs in genetic disorders like XLH, is characterized by significant unmet demand and premium pricing.

• XLH Market: The prevalence of XLH is estimated to be approximately 1 in 20,000 live births worldwide [6]. While considered a rare disease, the cumulative number of diagnosed patients represents a substantial market. The absence of approved treatments prior to CRYSVITA created a large, underserved patient population.
• TIO Market: TIO is even rarer, with an estimated incidence of less than 1 in 1,000,000 people per year [7]. However, the severity of the condition and the lack of effective pharmacological interventions prior to CRYSVITA have contributed to its significant value.

The market growth for CRYSVITA is driven by:

• Increased Diagnosis and Awareness: As awareness of XLH and TIO grows among physicians and patient advocacy groups, more patients are being diagnosed and identified as candidates for CRYSVITA therapy.
• Expansion of Indications: The approval for TIO in 2022 significantly broadened the addressable patient population.
• Geographic Expansion: Continued launches and market penetration in additional countries contribute to revenue growth.
• Pediatric Indications: Approvals for younger pediatric populations expand the eligible patient base from earlier in life.

While precise current market size figures for CRYSVITA are proprietary, analysts project continued strong revenue growth, driven by its orphan drug status and first-in-class therapy positioning.

What is the Competitive Landscape for CRYSVITA?

The competitive landscape for CRYSVITA is currently limited, primarily due to its first-in-class status and the rarity of its target indications.

• XLH: Prior to CRYSVITA, treatment for XLH primarily involved symptomatic management with high doses of oral phosphate supplements and active vitamin D metabolites. This approach often provided suboptimal control of phosphate levels, required frequent dosing, and was associated with significant side effects and treatment burdens. CRYSVITA offers a targeted therapy that addresses the underlying FGF23 excess, leading to improved efficacy and a better patient experience.
• TIO: Similar to XLH, the management of TIO was historically challenging, relying on surgical resection of the causative tumor or supportive care with phosphate and vitamin D supplementation. CRYSVITA provides a novel therapeutic option for patients where tumor resection is not possible or has failed to resolve the condition.

Pipeline Competition: While no direct biosimilar or generic competition is imminent for CRYSVITA due to its complex biologic nature and patent protections, research is ongoing into other FGF23-targeted therapies or alternative approaches to phosphate and vitamin D regulation in rare bone diseases. Companies are exploring different antibody formats or small molecule inhibitors that could potentially target FGF23 signaling or its downstream effects. However, these are generally in earlier stages of development and face the challenge of demonstrating superior efficacy, safety, or cost-effectiveness compared to the established CRYSVITA.

What is the Financial Performance and Trajectory of CRYSVITA?

CRYSVITA has demonstrated a robust financial performance since its launch, driven by strong demand and its premium pricing as an orphan drug.

Key Financial Highlights:

• Launch and Early Growth (2018-2019): Following its FDA approval in April 2018, CRYSVITA generated $131.7 million in net sales in 2018 [8]. By 2019, net sales grew to $375.4 million, indicating significant market adoption [8].
• Continued Expansion (2020-2022): The drug continued its upward trajectory. In 2020, net sales reached $525.3 million [8]. This grew to $621.3 million in 2021 and $725.7 million in 2022 [8].
• 2023 Performance: For the fiscal year 2023, CRYSVITA achieved net sales of $816.4 million [9]. This represents a substantial increase year-over-year and highlights sustained market penetration and patient uptake.
• Geographic Revenue Breakdown: The majority of CRYSVITA's revenue is generated in the United States, reflecting the early and strong market entry. International sales have been growing steadily as Takeda expands its global commercial efforts. For example, in 2023, U.S. net sales were $484.7 million, while international net sales were $331.7 million [9].

Factors Influencing Financial Trajectory:

• Pricing: As a novel therapy for rare, life-altering conditions, CRYSVITA commands a premium price, contributing significantly to its revenue generation. The annual cost of CRYSVITA therapy can range from tens of thousands to over a hundred thousand dollars per patient, depending on dosage and administration frequency.
• Sales Volume: The increasing number of diagnosed patients and the expansion of approved indications have led to consistent growth in sales volume.
• Reimbursement: Successful reimbursement strategies and market access in key countries are crucial for sustained sales. The economic value proposition of CRYSVITA, demonstrating improved patient outcomes and potentially reduced long-term healthcare costs associated with complications of XLH and TIO, supports its market access.
• Partnership Dynamics: The collaboration between Ultragenyx and Takeda is instrumental. Takeda's global commercial infrastructure and expertise in rare diseases facilitate broader market access and sales compared to Ultragenyx operating independently on a global scale. Royalties and profit-sharing agreements between the partners are structured to reflect their contributions. Ultragenyx reports its share of CRYSVITA sales and recognizes royalties from Takeda's international sales.

The financial trajectory of CRYSVITA suggests a mature growth phase with continued expansion potential, driven by its established efficacy, expanding market access, and the enduring unmet need in its target indications.

What are the Key Challenges and Risks for CRYSVITA?

Despite its success, CRYSVITA faces several challenges and risks that could impact its future trajectory.

• Pricing Pressure and Market Access: The high cost of orphan drugs is a persistent challenge. Healthcare systems worldwide are increasingly scrutinizing the cost-effectiveness of such therapies. Payers may implement stricter access criteria, require robust real-world evidence of value, or negotiate pricing, potentially limiting market penetration or growth.
• Long-Term Efficacy and Safety Monitoring: While clinical trials have demonstrated significant efficacy and an acceptable safety profile, ongoing monitoring of long-term outcomes is essential. Unexpected adverse events or waning efficacy over extended treatment periods could impact patient retention and physician prescribing habits.
• Competition: Although direct competition is limited, the development of alternative therapies, including potentially lower-cost generics or biosimil options for other targets in the FGF23 pathway, could emerge in the future. The emergence of such competitors, even if not directly targeting FGF23, could fragment the market.
• Diagnostic Challenges and Patient Identification: XLH and TIO are rare diseases, and diagnosis can be delayed or missed, especially in milder forms or in regions with limited diagnostic resources. Continued efforts in physician education and diagnostic support are necessary to identify the full patient population.
• Regulatory Hurdles for New Indications: While CRYSVITA has secured approvals for its current indications, seeking approval for new patient populations or alternative rare bone disorders would require extensive and costly clinical trials, facing rigorous regulatory scrutiny.
• Supply Chain and Manufacturing: As a biologic, the manufacturing of CRYSVITA is complex and requires specialized facilities and stringent quality control. Any disruption in the supply chain or manufacturing issues could impact product availability and revenue.
• Patent Expirations and Exclusivity: While CRYSVITA is protected by various patents, the long-term exclusivity of biologic drugs can eventually be challenged. The exact timing and impact of patent expirations will depend on jurisdiction and the specific patents involved.

What is the Future Outlook for CRYSVITA?

The future outlook for CRYSVITA remains positive, underpinned by its strong market position and the persistent unmet medical needs it addresses.

• Sustained XLH Market Dominance: CRYSVITA is expected to maintain its dominant position in the XLH market for the foreseeable future, given its first-in-class status and established efficacy. Continued efforts to increase diagnosis rates and patient access will drive incremental growth.
• Growth in TIO Market: The TIO indication represents a significant growth opportunity. As awareness of this condition and the therapeutic utility of CRYSVITA increases among oncologists and endocrinologists, patient identification and treatment are expected to expand.
• Geographic Expansion: Takeda's ongoing global commercialization efforts will likely lead to increased penetration in emerging markets and further solidify CRYSVITA's presence in established markets.
• Potential for New Indications: While not currently a major driver, any successful exploration of CRYSVITA for other FGF23-mediated disorders could open new avenues for growth, though this remains speculative and would require substantial R&D investment.
• Partnership Longevity: The collaboration between Ultragenyx and Takeda is critical. The continued alignment of strategic objectives and effective execution of commercial strategies will be key to maximizing CRYSVITA's long-term value.

CRYSVITA has successfully carved out and dominated a niche market. Its financial trajectory is a testament to its therapeutic value and the strategic execution of its development and commercialization. While competitive and regulatory challenges exist, the fundamental demand for effective treatments for rare metabolic bone diseases provides a strong foundation for CRYSVITA's continued success.

Key Takeaways

• CRYSVITA is the first approved therapy for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), directly addressing excess fibroblast growth factor 23 (FGF23).
• The drug has demonstrated a consistent and robust financial growth trajectory, with net sales reaching $816.4 million in 2023.
• Market expansion is driven by increasing diagnosis rates, new indications (TIO), geographic penetration, and the premium pricing associated with orphan drug status.
• The competitive landscape is currently limited, with CRYSVITA holding a first-in-class advantage.
• Key challenges include pricing pressures, potential future competition, and ongoing regulatory scrutiny for market access.
• The future outlook for CRYSVITA remains positive, with continued growth expected from its established XLH market, expanding TIO segment, and ongoing geographic expansion.

Frequently Asked Questions

1. What is the specific annual revenue contribution of CRYSVITA to Ultragenyx Pharmaceutical and Takeda Pharmaceutical Company? CRYSVITA generated $816.4 million in net sales globally in 2023. Ultragenyx Pharmaceutical, as the originator, recognizes a significant portion of these sales and receives royalties from Takeda on international sales. Specific profit-sharing and royalty figures are detailed in the companies' SEC filings and licensing agreements.

2. How does the pricing of CRYSVITA compare to traditional treatments for XLH, such as oral phosphate and vitamin D supplements? CRYSVITA is priced as a premium orphan drug, with annual treatment costs potentially ranging from tens of thousands to over one hundred thousand dollars per patient. This is substantially higher than the cost of oral phosphate and vitamin D supplements, which are significantly less expensive but often provide suboptimal efficacy and a greater treatment burden.

3. What is the patent protection status for CRYSVITA, and when can generic or biosimilar competition be expected? CRYSVITA is protected by multiple patents covering its composition of matter, manufacturing, and method of use. The exact expiration dates vary by jurisdiction. As a biologic, generic versions are not possible; biosimilar competition may emerge after patent exclusivities expire, but this process is complex and typically occurs many years after initial approval.

4. Beyond XLH and TIO, are there any other potential indications being investigated for CRYSVITA? While the primary focus remains on XLH and TIO, Ultragenyx and Takeda continually evaluate the potential of CRYSVITA for other FGF23-related disorders. However, no other indications are currently in late-stage clinical development or have announced plans for regulatory submission.

5. What is the typical patient journey from diagnosis of XLH or TIO to initiation of CRYSVITA therapy? The patient journey involves diagnosis by a specialist (e.g., pediatric endocrinologist, geneticist, nephrologist, rheumatologist), confirmation of disease severity and underlying cause (genetic testing for XLH, tumor localization for TIO). Once diagnosed and deemed a candidate, the patient's physician will prescribe CRYSVITA, and the pharmaceutical companies' patient support programs assist with insurance authorization and financial assistance.

Citations

[1] U.S. Food & Drug Administration. (2018, April 23). FDA approves first treatment for X-linked hypophosphatemia, a rare genetic rickets. U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-x-linked-hypophosphatemia-rare-genetic-rickets

[2] U.S. Food & Drug Administration. (2022, April 21). FDA approves CRYSVITA (burosumab-twlc) for the treatment of tumor-induced osteomalacia. U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-crysvita-burosumab-twlc-treatment-tumor-induced-osteomalacia

[3] Ultragenyx Pharmaceutical Inc. (2020, January 21). Ultragenyx and Takeda Announce FDA Approval of CRYSVITA® (burosumab-twlc) for Pediatric Patients with X-linked Hypophosphatemia. GlobeNewswire. Retrieved from https://www.globenewswire.com/news-release/2020/01/21/1973134/0/en/Ultragenyx-and-Takeda-Announce-FDA-Approval-of-CRYSVITA-burosumab-twlc-for-Pediatric-Patients-with-X-linked-Hypophosphatemia.html

[4] European Medicines Agency. (2018, February 21). Krystexxa EPAR Summary. European Medicines Agency. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/crysvita

[5] European Medicines Agency. (2020, December 17). Crysvita EPAR summary for the public: Tumor-induced osteomalacia. European Medicines Agency. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/crysvita

[6] Beck-Noren, K., & White, K. E. (2010). X-linked hypophosphatemia. In M. P. Adam, H. H. Ardinger, R. R. Hunter, & A. K. Mullikin (Eds.), GeneReviews®. University of Washington, Seattle.

[7] Cornish, J., & Pinedo, E. G. (2020). Tumor-induced osteomalacia. Bone, 137, 115457.

[8] Ultragenyx Pharmaceutical Inc. (2023, February 28). Ultragenyx Reports Fourth Quarter and Full Year 2022 Results. GlobeNewswire. Retrieved from https://www.globenewswire.com/news-release/2023/02/28/2616621/0/en/Ultragenyx-Reports-Fourth-Quarter-and-Full-Year-2022-Results.html

[9] Ultragenyx Pharmaceutical Inc. (2024, February 27). Ultragenyx Reports Fourth Quarter and Full Year 2023 Results. GlobeNewswire. Retrieved from https://www.globenewswire.com/news-release/2024/02/27/2837498/0/en/Ultragenyx-Reports-Fourth-Quarter-and-Full-Year-2023-Results.html